Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D, as the company faces down criticism of its recent efforts to develop and build its pipeline. He is ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow sales in the years ahead.

Pfizer Inc. has announced that Jeffrey Legos, PhD, MBA, will join the company as Chief Oncology Officer. In this role, Dr.

Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written over 40 manuscripts and abstracts for peer-reviewed journals. Further, he ...

Pfizer is laying down new pieces for its leadership ... Chief Oncology Officer and Executive Vice President Chris Boshoff, M.D., Ph.D., took on Dolsten’s position at the start of 2025, with ...

Second question is, Chris Boshoff, I assume he's on the line. Under the heading of nothing is perfect, can you share with us two or three things in the Pfizer R&D portfolio or system that you ...

Response (Chris Boshoff): Data from ongoing studies will guide decisions, and Pfizer is focusing on high-value opportunities within its four R&D units. Geoff Meacham, Citibank: Inquired about ...

Chris Boshoff, Pfizer’s chief oncology officer Its new chief oncology officer, Dr Chris Boshoff, said the focus will be on four main cancer types: breast cancer, genitourinary cancers including ...

2024--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer ...